1Stal O,Sullivan S,Wingren S,et al.C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer.Eur J Cancer,1995,31 A:2185-2190.
2Miles DW,Harris WH,Gillett CE,et aL.Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.Int J Cancer,1999,84:354-359.
3Menard S,Valagussa,P,Pilotti S,et al.Response to cyclophosphamide,methotrexate,and fluorouracil in lymph nodepositive breast cancer according to HER2 overexpression and other tumor biologic variables.J Clin Oncol,2001,19:329-335.
4Yang W,Klos KS,Zhou X,et al.ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2:poor responsiveness to chemotherapy with cyclophoshamide methotrexate,and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.Cancer,2003,98:1123-1130.
5Muss HB,Thor AD,Berry DA,et al.C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.N Eng J Med,1994,330:1260-1266.
6Petit T,Borel C,Ghnassia JP,et al.Chemotherapy response of breast cancer depends on HER-2 status and anthracyeline dose intensity in the neoadjuvant setting.Clin Cancer Res,2001,7:1577-1581.
7Ueno NT,Yu D,Hung MC.Chemosensitization of HER-2/neuoverexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.Oncogene,1997,15:953-960.
8Ciardiello F,Caputo R,Pomatico G,et al.Resistance to taxanes is induced by C-erbB-2 overexpressing in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.Int J Cancer,2000,85:710-715.
9Konecny GE,Thomssen C,Luck HJ,et al.Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.J Natl Cancer Inst,2004,96:1141-1151.
10Seidman AD,Founier MN,Esteva FJ,et al.Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.J Clin Onco1,2001,19:2587-2595.
